XCancer

Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients

Description:

The goal of this study is to investigate the safety of \[68Ga\]CBP8 and its efficacy to detect collagen deposition in pulmonary fibrosis.

Sponsor:

Massachusetts General Hospital

Phase:

Phase 1

Contacts:

Sydney B Montesi, MD (CONTACT)

sbmontesi@partners.org

617 724 4030

Abimbola Akinniyi (CONTACT)

aakinniyi@mgb.org

781 513 0207

Sydney B Montesi, MD (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT03535545 - Click here to see study on

ClinicalTrials.gov

CBP8

Isotope(s):
Target(s):
  • Collagen type I
Ligand Class: Small Molecules
Inclusion
  • Age greater than 18 years
  • Be deemed healthy at screening visit as determined by the physician investigator or nurse practitioner, based on the following assessments at Screening: physical examination, medical history, and vital signs
  • Total enrollment for all groups will not exceed 100 subjects.
  • Group 1: Healthy subjects
  • Have the ability to give written informed consent;
Exclusion
  • Pregnant or breastfeeding (a negative quantitative serum hCG pregnancy test is required for females having child-bearing potential before the subject can participate);
  • eGFR of less than 30 mL/min/1.73 m2 within the past 90 days for group 4 subjects; history of chronic kidney disease for subjects in groups 1-3 and 5;
  • * Electrical implants such as cardiac pacemaker or perfusion pump;
  • Claustrophobic reactions;
  • Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, or steel implants ferromagnetic objects such as jewelry or metal clips in clothing;